

[The decisions of the Formulary Group meeting \(Tuesday 18 June 2024\) will be published by 03 July 2024.](#)

Publication schedule

This information is updated monthly.

Formulary Group work programme

The Group meets monthly on the third Tuesday of each month (excluding July and December). The following list includes medicines that will be scheduled for review in the next three to four months. It is indicative and may be subject to change.

Medicine and indication	Meeting date
acarbose 50mg, 100mg tablets	
Formulary review	
Indication: recommended for the treatment of type 2 diabetes (non-insulin dependent) in patients inadequately controlled on diet alone, or on diet and (i) metformin and / or (ii) a sulphonylurea.	Jun 2024
atovaquone 750mg/5mL oral suspension	
FG1 451/22	
Indication: (off-label) for the prevention of Pneumocystis carinii pneumonia.	
Restriction: second-line option for patients where co-trimoxazole is not effective, not tolerated or contraindicated.	TBC
clonidine 25micrograms, 100micrograms tablets	
Formulary review	
Indication: off-label for children and adolescents 6 years and older for the management of ADHD in those unresponsive to or unable to tolerate treatment with stimulants, atomoxetine or guanfacine.	Jun 2024
dostarlimab 500mg concentrate for solution for infusion (Jemperli®)	
SMC 2635	
Indication: in combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy.	Sep 2024
dulaglutide 0.75mg, 1.5mg, 3mg, 4.5mg solution for injection in pre-filled pen (Trulicity®)	
Formulary review 1110/15	
Indication: in adults with type 2 diabetes mellitus to improve glycaemic control as add-on therapy in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.	
SMC restriction: as part of a triple therapy in patients with inadequate glycaemic control on two oral anti-diabetic drugs, as an alternative glucagon-like peptide 1 (GLP-1) agonist option.	Jun 2024

Medicine and indication	Meeting date
<p>ertugliflozin L-pyroglutamic acid 5mg, 15mg tablets Formulary review 2102</p> <p>Indication: in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: As monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications. In addition to other medicinal products for the treatment of diabetes.</p> <p>SMC restriction: ertugliflozin is accepted for use as monotherapy and as add-on therapy. When used as monotherapy it is restricted to patients who would otherwise receive a dipeptidyl peptidase-4 inhibitor and in whom a sulphonylurea or pioglitazone is not appropriate.</p>	<p>Jun 2024</p>
<p>exenatide 2mg powder and solvent for prolonged-release suspension for injection (Bydureon®) Formulary review 748/11</p> <p>Indication: treatment of type 2 diabetes mellitus in combination with:</p> <ul style="list-style-type: none"> - metformin - sulphonylurea - thiazolidinedione - metformin and sulphonylurea - metformin and thiazolidinedione in adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies. <p>SMC restriction: exenatide once weekly is restricted to use as a third line treatment option.</p>	<p>Jun 2024</p>
<p>foslevodopa-foscarbidopa 240mg/mL + 12mg/mL solution for infusion (Produodopa®) SMC 2574</p> <p>Indication: treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.</p> <p>SMC restriction: for use in patients not eligible for deep brain stimulation (DBS).</p>	<p>Jun 2024</p>
<p>glofitamab 2.5mg, 10mg concentrate for solution for infusion (Columvi®) SMC 2614</p> <p>Indication: as monotherapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.</p>	<p>TBC</p>

Medicine and indication	Meeting date
<p>GoResp® Digihaler® 160micrograms/4.5micrograms, 320micrograms/9micrograms budesonide / formoterol fumarate dihydrate</p> <p>Formulary review</p> <p>Indication: GoResp Digihaler is indicated in adults 18 years of age and older only.</p> <p>Asthma</p> <p>GoResp Digihaler is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate:</p> <ul style="list-style-type: none"> -in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists. or -in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists. <p>COPD</p> <p>Symptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV1) < 70% predicted normal (post bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.</p>	<p>Jun 2024</p>
<p>ivosidenib 250mg film-coated tablet (Tibsovo®)</p> <p>SMC 2615</p> <p>Indication: in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.</p>	<p>Aug 2024</p>
<p>liraglutide 6mg/mL solution for injection in pre-filled pen (Saxenda®)</p> <p>SMC 2455</p> <p>Indication: as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of: 1) ≥30kg/m² (obese), or 2) ≥27kg/m² to <30kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.</p> <p>SMC restriction: BMI ≥35kg/m²* (obesity class II and above) with:</p> <ul style="list-style-type: none"> - Non-diabetic hyperglycaemia (prediabetes) at high risk of type 2 diabetes which is defined as having either: <ul style="list-style-type: none"> o Fasting plasma glucose level of 5.5 to 6.9mmol/L or o HbA1c of 6.0 to 6.4% (42 to 47mmol/mol), and - High risk of cardiovascular disease (CVD): <ul style="list-style-type: none"> o Total cholesterol >5mmol/L, or o High-density lipoprotein (HDL) <1.0mmol/L for men and <1.3mmol/L for women, or o Systolic blood pressure (SBP) >140mmHg. <p>Patients should be treated in a specialist weight management service.</p> <p>*a lower BMI cut-off may be more appropriate for members of minority</p>	<p>Jun 2024</p>

Medicine and indication	Meeting date
ethnic groups known to be at equivalent risk of the consequences of obesity at a lower BMI than the white population.	
mavacamten 2.5mg, 5mg, 10mg, 15mg hard capsules (Camzyos®)	
SMC 2618	
Indication: treatment of symptomatic (New York Heart Association, NYHA, class II to III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients.	Aug 2024
mirikizumab 100mg, 300mg solution for injection in pre-filled pen and concentrate for solution for infusion (Omvoh®)	
SMC 2650	
Indication: for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.	Aug 2024
momelotinib 100mg, 150mg, 200mg film coated tablet (Omjjara®)	
SMC 2636	
Indication: for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.	TBC
repaglinide 0.5mg, 1mg, 2mg tablets	
Formulary review	
Indication: adults with type 2 diabetes mellitus whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. Repaglinide is also indicated in combination with metformin in adults with type 2 diabetes mellitus who are not satisfactorily controlled on metformin alone.	Jun 2024
ribociclib 200mg film-coated tablets (Kisqali®)	
SMC 2198	
Indication: for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant* as initial endocrine-based therapy, or in women who have received prior endocrine therapy.	TBC
SMC restriction: women who have relapsed on or within 12 months of completing (neo) adjuvant endocrine therapy, or those who have progressed on first-line endocrine-based therapy for advanced breast cancer.	
ritlecitinib tosylate 50mg hard capsules (Litfulo®)	
SMC 2610	
Indication: for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.	Sep 2024

Medicine and indication	Meeting date
<p>secukinumab 150mg, 300mg solution for injection in pre-filled pen or pre-filled syringe (Cosentyx®)</p> <p>SMC 2592</p> <p>Indication: for the treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adults with an inadequate response to conventional systemic HS therapy.</p> <p>SMC restriction: for use in adult patients with active moderate to severe HS for whom adalimumab is contraindicated or otherwise unsuitable, including those who have failed to respond or have lost response to prior adalimumab treatment.</p>	<p>Sep 2024</p>
<p>selpercatinib 40mg, 80mg hard capsules (Retsevmo®)</p> <p>SMC 2573</p> <p>Indication: monotherapy for the treatment of adults with advanced rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor.</p> <p>SMC restriction: for use in treatment-naïve patients who have not previously received a RET-inhibitor or any other systemic treatments for their advanced stage of disease.</p>	<p>Jun 2024</p>
<p>semaglutide 0.25mg, 0.5mg, 1mg, 2mg solution for injection in pre-filled pen (Ozempic®)</p> <p>Formulary review 2092</p> <p>Indication: the treatment of adults with insufficiently controlled type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise:</p> <ul style="list-style-type: none"> - as monotherapy when metformin is considered inappropriate due to intolerance or contraindications - in addition to other medicinal products for the treatment of diabetes. <p>SMC restriction: In addition to other oral anti-diabetic medicines, or as an add-on to basal insulin, as an alternative glucagon-like peptide-1 receptor agonist option.</p>	<p>Jun 2024</p>
<p>semaglutide 3mg, 7mg and 14mg tablets (Rybelsus®)</p> <p>SMC 2287</p> <p>Indication: for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise</p> <ul style="list-style-type: none"> - as monotherapy when metformin is considered inappropriate due to intolerance or contraindications - in combination with other medicinal products for the treatment of diabetes. <p>SMC restriction: In addition to other oral anti-diabetic medicines, or as an add-on to basal insulin, as an alternative glucagon-like peptide-1 receptor agonist option.</p>	<p>Jun 2024</p>

Medicine and indication	Meeting date
<p>sodium zirconium cyclosilicate 5g and 10g powder for oral suspension (Lokelma®)</p> <p>SMC 2288</p> <p>Indication: for the treatment of hyperkalaemia in adult patients.</p> <p>SMC restriction: patients with hyperkalaemia (defined as a serum potassium of >6.0mmol/L) with chronic kidney disease (CKD) stage 3b to 5 and/or heart failure who would otherwise need to down-titrate or discontinue their renin-angiotensin-aldosterone system inhibitor (RAASi) therapy to maintain a clinically acceptable serum potassium level (normokalaemia)</p>	Aug 2024
<p>tirzepatide 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg solution for injection in pre-filled pen (Mounjaro®)</p> <p>SMC 2633</p> <p>Indication: for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise: - as monotherapy when metformin is considered inappropriate due to intolerance or contraindications - in addition to other medicinal products for the treatment of diabetes.</p> <p>SMC restriction: in addition to other oral anti-diabetic medicines as an option when glucagon-like peptide-1 (GLP-1) receptor agonists would be considered.</p>	Jun 2024
<p>SMC 2653</p> <p>Indication: for weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial Body Mass Index (BMI) of ≥ 30 kg/m² (obesity) or ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).</p> <p>SMC restriction: for use in adults with BMI ≥ 30 kg/m²* and at least one weight-related comorbidity.</p> <p>*a lower BMI cut-off may be more appropriate for members of minority ethnic groups known to be at equivalent risk of the consequences of obesity at a lower BMI than the white population.</p>	Jun 2024
<p>Xonvea® 10 mg/10 mg gastro-resistant tablets (doxylamine succinate/pyridoxine hydrochloride)</p> <p>FG1 450/22</p> <p>Indication: Severe nausea and vomiting in pregnancy (NVP) and Hyperemesis gravidarum (HG)</p>	TBC

END